Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Sny save search
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
Published: 2023-11-22 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
ibi362 publication care chinese diabetes results phase 2
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
Published: 2023-11-05 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
MLTX | $42.19 -0.14% -0.14% 530K
|
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
nanobody active results phase 2
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474
Published: 2023-10-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -5.43%
kt-474 trial therapeutics phase 2
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Published: 2023-06-25 (Crawled : 16:20) - globenewswire.com
MLTX | $42.19 -0.14% -0.14% 530K
|
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
nanobody positive results milestone phase 2
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.42%
H: 0.0%
C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: 1.84%
H: 6.63%
C: 4.82%
pharma results study phase 2
AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain
Published: 2023-03-14 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.13%
H: 0.0%
C: -0.22%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
atx01 program phase 2
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 1.41%
C: 1.41%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.39%
H: 0.0%
C: 0.0%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: 0.3%
H: 1.51%
C: 1.45%
trial therapeutics sanofi sclerosis milestone phase 2 multiple sclerosis
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
Published: 2022-12-14 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.88%
H: 0.48%
C: -0.21%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: 0.0%
nanobody active study phase 2
Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
Published: 2022-12-12 (Crawled : 15:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.34%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -2.65%
H: 2.02%
C: 1.69%
phase 2
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
cd20 phase 2
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
Published: 2022-12-08 (Crawled : 14:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
fda designation drug candidate granted phase 2
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Published: 2022-09-26 (Crawled : 12:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
nanobody global active study phase 2
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
Published: 2022-09-23 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 5.45%
H: 0.0%
C: -8.46%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.53%
H: 0.81%
C: 0.14%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.69%
H: 0.0%
C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: -2.02%
H: 0.41%
C: -3.72%
ongoing pharma trial phase 2
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
Published: 2022-09-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
obesity chinese trial phase 2
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.64%
H: 1.24%
C: 0.07%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.56%
H: 1.41%
C: -0.34%
treatment nephropathy positive study phase 2
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
Published: 2022-08-10 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -6.43%
H: 0.0%
C: -6.31%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.49%
H: 0.86%
C: 0.04%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 1.13%
H: 0.52%
C: -0.58%
ibi112 chinese psoriasis study plague phase 2
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 1.59%
H: 0.68%
C: -2.46%
treatment nephropathy topline positive phase 2
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
Published: 2022-06-03 (Crawled : 08:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -0.32%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.65%
H: 0.63%
C: 0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: 2.96%
H: 0.98%
C: -1.15%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
iph5201 pharma cancer phase 2
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
Published: 2022-05-12 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.78%
H: 0.61%
C: 0.49%
nanobody trial phase 2
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
Published: 2022-05-02 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.05%
H: 0.0%
C: 0.0%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: -6.34%
H: 6.77%
C: 6.48%
als trial therapeutics sanofi milestone phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.